• KOLs Community
    • Ischaemic
    • Ischaemic Stroke
    • Robin Lemmens
    • Robin Lemmens

      Robin Lemmens

      Department of Neurology, University Hospitals Leuven, Leuven, Belgium | Department of Neuroscience, Katholieke Universiteit Leuven, Campus Gasthuisberg O&N2; Leuven (BE-3000), ...



      KOL Resume for Robin Lemmens


      Department of Neurology, University Hospitals Leuven, Leuven, Belgium


      Department of Neurosciences, Experimental Neurology, KU Leuven–University of Leuven; VIB Center for Brain & Disease Research; Department of Neurology, University Hospitals Leuven, Leuven, Belgium


      Department of Neuroscience, Katholieke Universiteit Leuven, Campus Gasthuisberg O&N2; Herestraat 49 box 1021; Leuven (BE-3000), Belgium


      Experimental Neurology and Leuven Institute for Neuroscience and Disease, Katholieke Universiteit Leuven, University of Leuven, Laboratory of Neurobiology, Leuven, Belgium

      Department of Neurology, University Hospitals Leuven (R.L.).


      Dept of Neurosciences, Experimental Neurology and Leuven Rsch Institute for Neuroscience a, KU - Univ of Leuven, Leuven, Belgium

      University Hospitals Leuven. Netherlands


      From Department of Neurology, University of California, San Francisco (J.D.E.); AstraZeneca, Gothenburg, Sweden (M.A., S.B.-S., H.D., P.H., M.J., J.J.); Stanford University Medical Center, Stanford Stroke Center, Palo Alto, CA (G.W.A.); Department of Neurology and Stroke Center, Bichat University Hospital and Medical School, Paris, France (P.A.); Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA (S.R.E.); National Cerebral and Cardiovascular Center, Suita, Osaka, Japan (K.M.); Stroke Unit, Hospital Vall d’Hebron, Barcelona, Spain (C.A.M.); Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, China (Y.W.); Department of Medicine and Therapeutics, Chinese University of Hong Kong, China (K.S.L.W.); and Dean’s Office, Dell Medical School, University of Texas, Austin (S.C.J.).

      Stanford University, Stanford, CA, USA


      Service of Neurology (University Hospital Leuven) and Laboratory for Neurobiology, Section of Experimental Neurology, University of Leuven, Leuven B-3000, Belgium



      Robin Lemmens: Influence Statistics

      Sample of concepts for which Robin Lemmens is among the top experts in the world.
      Concept World rank
      goals 59 #9
      eas levels #9
      esc eas belgium #9
      497 enrolled patients #9
      attainment belgium #9
      observational vinci #9
      prescribed llt regimen #9
      belgium vinci #9
      achieved 2016 #15
      belgium cvd #16
      attainment 2019 #17
      goals 2016 #18
      prescribed llt #21
      vinci observational #22
      vinci observational study #22
      achieved 2019 #27
      oxazoles stroke #27
      riskbased ldlc goals #29
      guidelines 41 #29
      α5 antagonist #32
      illness ticagrelor aspirin #33
      doubleblind thales #33
      ipsilateral atherosclerosis #33
      stenosis cervicocranial #33
      34 95 patients #34
      brainresident tregs #34
      5q332 locus #35
      total 5876 #35
      mapping smr #35
      2p251 2q312 #35
      smr adam23 #35
      gria1 enriched #35
      adam23 log #35
      analyses nominated #35
      87 δnihss #35
      suggested gria1 #35
      humans excitotoxicity #35
      δnihss total #35
      2q312 2q333 #35
      ischemic stroke ticagrelor #36
      acute nonsevere #37
      δnihss variance #38
      parenchymal haematoma type #38
      deteriorate early #39
      cervicocranial vasculature #39
      treat 34 #39
      loci 1p211 #40
      7p211 loci #40
      early outcomes hours #40
      excitotoxic genes #40


      Prominent publications by Robin Lemmens

      KOL-Index: 18820

      BACKGROUND: Patients with minor acute ischemic stroke or transient ischemic attack are at high risk for subsequent stroke, and more potent antiplatelet therapy in the acute setting is needed. However, the potential benefit of more intense antiplatelet therapy must be assessed in relation to the risk for major bleeding. The SOCRATES trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes) was the first trial with ticagrelor in patients with ...

      Known for Transient Ischemic Attack | Acute Stroke | Ticagrelor Aspirin | Major Bleeding | Antiplatelet Therapy
      KOL-Index: 18776

      BACKGROUND: Cerebral microbleeds are a neuroimaging biomarker of stroke risk. A crucial clinical question is whether cerebral microbleeds indicate patients with recent ischaemic stroke or transient ischaemic attack in whom the rate of future intracranial haemorrhage is likely to exceed that of recurrent ischaemic stroke when treated with antithrombotic drugs. We therefore aimed to establish whether a large burden of cerebral microbleeds or particular anatomical patterns of cerebral ...

      Known for Ischaemic Stroke | Cerebral Microbleeds | Intracranial Haemorrhage | Pooled Analysis | Individual Patient Data
      KOL-Index: 13555

      BACKGROUND AND PURPOSE: Among patients with a transient ischemic attack or minor ischemic strokes, those with ipsilateral atherosclerotic stenosis of cervicocranial vasculature have the highest risk of recurrent vascular events.

      METHODS: In the double-blind THALES (The Acute Stroke or Transient Ischemic Attack Treated With Ticagrelor and ASA for Prevention of Stroke and Death) trial, we randomized patients with a noncardioembolic, nonsevere ischemic stroke, or high-risk transient ...

      Known for Ischemic Stroke | Ticagrelor Aspirin | Hazard Ratio | Attack Transient | 30 Patients
      KOL-Index: 12537

      BACKGROUND: The value of administering intravenous alteplase before endovascular treatment (EVT) for acute ischemic stroke has not been studied extensively, particularly in non-Asian populations.

      METHODS: We performed an open-label, multicenter, randomized trial in Europe involving patients with stroke who presented directly to a hospital that was capable of providing EVT and who were eligible for intravenous alteplase and EVT. Patients were randomly assigned in a 1:1 ratio to receive ...

      Known for Intravenous Alteplase | Endovascular Treatment | Evt Patients | Modified Rankin Scale | Functional Outcome
      KOL-Index: 8822

      BACKGROUND: Patients who have had a stroke with unknown time of onset have been previously excluded from thrombolysis. We aimed to establish whether intravenous alteplase is safe and effective in such patients when salvageable tissue has been identified with imaging biomarkers.

      METHODS: We did a systematic review and meta-analysis of individual patient data for trials published before Sept 21, 2020. Randomised trials of intravenous alteplase versus standard of care or placebo in adults ...

      Known for Intravenous Alteplase | Patients Stroke | Functional Outcome | Time Onset | Dwi Flair
      KOL-Index: 7856

      AIMS: To provide contemporary data on the implementation of European guideline recommendations for lipid-lowering therapies (LLTs) across different settings and populations and how this impacts low-density lipoprotein cholesterol (LDL-C) goal achievement.

      METHODS AND RESULTS: An 18 country, cross-sectional, observational study of patients prescribed LLT for primary or secondary prevention in primary or secondary care across Europe. Between June 2017 and November 2018, data were collected ...

      Known for Secondary Primary | Patients Llt | Sectional Observational | Vinci Study | 2019 Goals
      KOL-Index: 7766

      OBJECTIVES: To assess the association between cerebral microbleeds (CMBs) and future spontaneous intracerebral hemorrhage (ICH) risk in ischemic stroke patients with nonvalvular atrial fibrillation (AF) taking oral anticoagulants.

      METHODS: This was a meta-analysis of cohort studies with >50 patients with recent ischemic stroke and documented AF, brain MRI at baseline, long-term oral anticoagulation treatment, and ≥6 months of follow-up. Authors provided summary-level data on stroke ...

      Known for Hemorrhage Risk | Presence Cmb | Brain Microbleeds | Ischemic Stroke | Oral Anticoagulants
      KOL-Index: 7603

      OBJECTIVE: For 3,670 stroke patients from the United Kingdom, United States, Australia, Belgium, and Italy, we performed a genome-wide meta-analysis of white matter hyperintensity volumes (WMHV) on data imputed to the 1000 Genomes reference dataset to provide insights into disease mechanisms.

      METHODS: We first sought to identify genetic associations with white matter hyperintensities in a stroke population, and then examined whether genetic loci previously linked to WMHV in community ...

      Known for White Matter | Stroke Patients | Genetic Associations | Genome Wide | Disease Mechanisms
      KOL-Index: 6890

      OBJECTIVE: To measure the global impact of COVID-19 pandemic on volumes of IV thrombolysis (IVT), IVT transfers, and stroke hospitalizations over 4 months at the height of the pandemic (March 1 to June 30, 2020) compared with 2 control 4-month periods.

      METHODS: We conducted a cross-sectional, observational, retrospective study across 6 continents, 70 countries, and 457 stroke centers. Diagnoses were identified by their ICD-10 codes or classifications in stroke databases.

      RESULTS: There ...

      Known for Global Impact | Covid19 Stroke | 6 Continents | 70 Countries | Retrospective Studies
      KOL-Index: 6266

      Amyotrophic lateral sclerosis (ALS) is a spontaneous, relentlessly progressive motor neuron disease, usually resulting in death from respiratory failure within 3 years. Variation in the genes SOD1 and TARDBP accounts for a small percentage of cases, and other genes have shown association in both candidate gene and genome-wide studies, but the genetic causes remain largely unknown. We have performed two independent parallel studies, both implicating the RNA polymerase II component, ELP3, ...

      Known for Elongator Protein | Neuron Degeneration | Elp3 Gene | Male Mice Mice | Aged Motor
      KOL-Index: 6213

      BACKGROUND: S44819, a selective GABAA α5 receptor antagonist, reduces tonic post-ischaemic inhibition of the peri-infarct cortex. S44819 improved stroke recovery in rodents and increased cortical excitability in a transcranial magnetic stimulation study in healthy volunteers. The Randomized Efficacy and Safety Trial of Oral GABAA α5 antagonist S44819 after Recent ischemic Event (RESTORE BRAIN) aimed to evaluate the safety and efficacy of S44819 for enhancing clinical recovery of patients ...

      Known for Stroke Treatment | Antagonist S44819 | Gabaa Α5 | Tonic Inhibition | Brain Ischemia
      KOL-Index: 5835

      RATIONALE: Ischemic stroke is among the leading causes of adult disability. Part of the variability in functional outcome after stroke has been attributed to genetic factors but no locus has been consistently associated with stroke outcome.

      OBJECTIVE: Our aim was to identify genetic loci influencing the recovery process using accurate phenotyping to produce the largest GWAS (genome-wide association study) in ischemic stroke recovery to date.

      METHODS AND RESULTS: A 12-cohort, 2-phase ...

      Known for Functional Outcome | Ischemic Stroke | Genetic Factors | Genome Wide | Common Variants
      KOL-Index: 5547

      OBJECTIVE: To examine etiologic stroke subtypes and vascular risk factor profiles and their association with white matter hyperintensity (WMH) burden in patients hospitalized for acute ischemic stroke (AIS).

      METHODS: For the MRI Genetics Interface Exploration (MRI-GENIE) study, we systematically assembled brain imaging and phenotypic data for 3,301 patients with AIS. All cases underwent standardized web tool-based stroke subtyping with the Causative Classification of Ischemic Stroke ...

      Known for Ischemic Stroke | White Matter | Hyperintensity Burden | Diabetes Mellitus | Deep Learning
      KOL-Index: 5451

      OBJECTIVE: To discover common genetic variants associated with poststroke outcomes using a genome-wide association (GWA) study.

      METHODS: The study comprised 6,165 patients with ischemic stroke from 12 studies in Europe, the United States, and Australia included in the GISCOME (Genetics of Ischaemic Stroke Functional Outcome) network. The primary outcome was modified Rankin Scale score after 60 to 190 days, evaluated as 2 dichotomous variables (0-2 vs 3-6 and 0-1 vs 2-6) and subsequently ...

      Known for Functional Outcome | Ischemic Stroke | Genome Wide | Genetic Variant | Brain Ischemia
      KOL-Index: 4534

      BACKGROUND: Within randomized clinical trials (RCTs), coiling of the ruptured aneurysm to prevent rebleeding results in better outcomes than clipping in patients with aneurysmal subarachnoid hemorrhage (aSAH).

      OBJECTIVE: To study the association of coiling and clipping with outcome after aSAH in daily clinical practice.

      METHODS: In this controlled, nonrandomized study, we compared outcomes after endovascular coiling and neurosurgical clipping of ruptured intracranial aneurysms in an ...

      Known for Subarachnoid Hemorrhage | Clipping Coiling | Aneurysm Ruptured | Endovascular Procedures | Humans Intracranial

      Key People For Ischaemic Stroke

      Top KOLs in the world
      Harold P Jr Adams
      ischemic stroke cerebral infarction subarachnoid hemorrhage
      Ralph L Sacco
      ischemic stroke northern manhattan study carotid plaque
      Laurens Jaap Kappelle
      ischemic stroke type 2 diabetes cognitive impairment
      Hanschristoph C Diener
      atrial fibrillation cluster headache chronic migraine
      Graeme J Hankey
      atrial fibrillation global burden ischemic stroke
      José Biller
      ischemic stroke cerebral infarction neurologic complications

      Robin Lemmens:Expert Impact

      Concepts for whichRobin Lemmenshas direct influence:Ischaemic stroke,  Intravenous alteplase,  Ischemic stroke,  Cerebral microbleeds,  Functional outcome,  Stroke patients,  Transient ischemic attack,  Cerebral venous thrombosis.

      Robin Lemmens:KOL impact

      Concepts related to the work of other authors for whichfor which Robin Lemmens has influence:Ischemic stroke,  Cerebral microbleeds,  Amyotrophic lateral sclerosis,  Atrial fibrillation,  Bempedoic acid,  Intravenous thrombolysis,  Cerebrovascular disease.



      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Department of Neurology, University Hospitals Leuven, Leuven, Belgium | Department of Neuroscience, Katholieke Universiteit Leuven, Campus Gasthuisberg O&N2; Leuven (BE-3000), Belgium. | KU Leuven - Department of Neurosciences, Leuven 3000, Belgium |

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.